Jean-Antoine Ribeil, M.D., Ph.D. - Faculty Profile

Biography

Jean-Antoine Ribeil, M.D., Ph.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Hematology and Oncology. He serves as Director of the Comprehensive Adult Sickle Cell Disease Program.

Dr. Ribeil earned his medical degree at the University of Limoges in France and his doctorate in blood cell biology at Paris VII University. He completed a residency in hematology and oncology at the University of Limoges. He gained advanced training through clinical fellowships in intensive care, internal medicine, and hematology at the University of Limoges and Necker-Enfants Malades Hospital/Paris V Descartes University in Paris. He also completed a research fellowship in hematopoiesis and immunology at the French National Centre for Scientific Research in Paris.

Before joining the UT Southwestern faculty in 2025, Dr. Ribeil served as an associate professor at Boston University School of Medicine and was clinical director and then director of the Sickle Cell Center of Excellence, co-director of the Hereditary Hemorrhagic Telangiectasia Clinic, and principal investigator of the GLOB Lab at Boston Medical Center.

Dr. Ribeil has a strong focus on translational research and the development of gene therapy for hemoglobinopathies such as sickle cell disease and thalassemia. He has served as principal investigator or co-investigator on numerous industry- and foundation-supported studies and clinical trials evaluating novel pharmacologic agents, red blood cell exchange strategies, and innovative care models for people living with sickle cell disease. He is the former medical director of the gene therapy sickle cell disease program at Bluebird Bio in Cambridge, Massachusetts, and the founder and CEO of GLOB Therapy Consulting. He has delivered numerous regional and international invited lectures, contributed to textbooks, and published more than 80 academic articles related to his areas of expertise.

Dr. Ribeil is a member of the American Society of Gene & Cell Therapy and the American Society of Hematology. He serves on the editorial board of the American Journal of Hematology. He previously served on French national committees for the Sickle Cell Disease Centers of Excellence and the Thrombotic Microangiopathy Centers of Excellence.

Personal Note

When he's not at work, Dr. Ribeil enjoys traveling with his family, bicycling with friends, and cooking.

Education

Graduate School: Aix-Marseille University: Faculty of Medical and Paramedical Sciences (1995)
Medical School: University of Limoges, France (2001)
Internship: University of Limoges, France (2001), Hematology Oncology
Clinical Fellowship: Necker-Enfants Malades Hospital, France (2001), Hematology

Research Interest

Development of Gene Therapy for Hemoglobinopathies
Translational Research for Hemoglobinopathies

Publications

Featured Publications

Selective AMPKβ1 activation induces fetal hemoglobin in human erythroid cells and sickle cell mice via the noncanonical NRF2 pathway.: Hara Y, Lemgart VT, Lessard S, Mercadante CJ, Ribeil JA, Hicks A, Rimmele P, Light DR, Sci Adv 2025 Nov 11 47 eadx1144
From Where It Stems.: Shapira-Daniels A, Pareek K, Cozzolino M, Ribeil JA, Awtry E, N Engl J Med 2025 Jun 392 21 2151-2158
Initial outcomes in a sickle cell disease transition clinic.: Madrazo-Aguirre K, Ribeil JA, Sobota AE, Health Care Transit 2024 2 100056
Gene-addition/editing therapy in sickle cell disease.: Pollock G, Negre O, Ribeil JA, Presse Med 2023 Dec 52 4 104214
An integrated therapeutic approach to sickle cell disease management beyond infancy.: Ribeil JA, Pollock G, Frangoul H, Steinberg MH, Am J Hematol 2023 Jul 98 7 1087-1096
SGK1 inhibition induces fetal hemoglobin expression and delays polymerization in sickle erythroid cells.: Hara Y, Lemgart VT, Halland N, Mahdaviani K, Ribeil JA, Lessard S, Hicks A, Light DR, Blood Adv 2023 Jun 7 11 2317-2323
Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.: Kanter J, Thompson AA, Pierciey FJ, Hsieh M, Uchida N, Leboulch P, Schmidt M, Bonner M, Guo R, Miller A, Ribeil JA, Davidson D, Asmal M, Walters MC, Tisdale JF, Am J Hematol 2023 Jan 98 1 11-22
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.: Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, Aygun B, Kasow KA, Pierciey FJ, Bonner M, Miller A, Zhang X, Lynch J, Kim D, Ribeil JA, Asmal M, Goyal S, Thompson AA, Tisdale JF, N Engl J Med 2022 Feb 386 7 617-628
Pregnancy outcome in women with transfused beta-thalassemia in France.: Virot E, Thuret I, Jardel S, Herbrecht R, Lachenal F, Lionnet F, Lucchini MJ, Machin J, Nimubona S, Ribeil JA, Galacteros F, Cannas G, Hot A, Ann Hematol 2022 Feb 101 2 289-296
Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.: Magrin E, Semeraro M, Hebert N, Joseph L, Magnani A, Chalumeau A, Gabrion A, Roudaut C, Marouene J, Lefrere F, Diana JS, Denis A, Neven B, Funck-Brentano I, Negre O, Renolleau S, Brousse V, Kiger L, Touzot F, Poirot C, Bourget P, El Nemer W, Blanche S, Tréluyer JM, Asmal M, Walls C, Beuzard Y, Schmidt M, Hacein-Bey-Abina S, Asnafi V, Guichard I, Poirée M, Monpoux F, Touraine P, Brouzes C, de Montalembert M, Payen E, Six E, Ribeil JA, Miccio A, Bartolucci P, Leboulch P, Cavazzana M, Nat Med 2022 Jan 28 1 81-88

Honors & Awards

Poster Presentation Award, First Prize
Iron Overload Workshop (2013)
Poster Presentation Award, Second Prize
Iron Overload Workshop (2013)
Presentation Award
French Society of Hematology (2012)
Horiba Abx Cellular Hematology Award
French Society of Hematology (2007)
René Descartes Award
Congress of Young Researchers in Biology (2007)
Clinical Fellow Gold Medal
University of Limoges (2000)

Professional Associations/Affiliations

American Society of Gene & Cell Therapy
American Society of Hematology